Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 12, 2010, Pages 1629-1648

  Fruehauf, Stefan ^a   Tricot, Guido ^b  

^a Paracelsus Klinik   (Germany)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

G CSF; Hematopoietic stem cells; Immune effector cells; Mobilization; Plerixafor; Tumor cells

Indexed keywords

CELL MARKER; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; PLERIXAFOR; PROTEIN GROBETA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW; BONE MARROW CELL; CD3+ T LYMPHOCYTE; CD34 SELECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE; CELL HOMING; CELL POLARITY; CELL TYPE; CELL VIABILITY; CONTAMINATION; DENDRITIC CELL; DISEASE FREE SURVIVAL; DONOR; EFFECTOR CELL; ENGRAFTMENT; GENE EXPRESSION PROFILING; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOCYTE COUNT; LYMPHOMA; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGRESSION FREE SURVIVAL; PROTEIN PROTEIN INTERACTION; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL; STEM CELL MOBILIZATION; STROMA CELL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; TREATMENT OUTCOME;

EID: 78149409049     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.02.002     Document Type: Review

References (218)

1. Osgood E.E., Riddle M.C., Mathews T.J. Aplastic anemia treated with daily transfusions and intravenous marrow. Ann Intern Med 1939, 13:357-367.
2. Morrison M., Samwick A.A. Intramedullary (sternal) transfusion of human bone marrow. JAMA 1940, 115:1708-1711.
3. Thomas E.D., Buckner C.D., Banaji M., et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977, 49:511-533.
4. Mathe G., Amiel J.L., Schwarzenberg L., et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 1965, 25:1525-1531.
5. van Bekkum D.W., de Vries M.J. Radiation Chimeras 1967, Academic Press, New York.
6. Thomas E., Storb R., Clift R.A., et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975, 292:832-843.
7. Thomas E.D., Storb R., Clift R.A., et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975, 292:895-902.
8. Reiffers J., Bernard P., David B., et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 1986, 14:312-315.
9. Korbling M., Dorken B., Ho A.D., et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986, 67:529-532.
10. Kessinger A., Armitage J.O., Landmark J.D., et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986, 14:192-196.
11. Juttner C.A., To L.B., Haylock D.N., et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high-dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985, 61:739-745.
12. Duhrsen U., Villeval J.L., Boyd J., et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988, 72:2074-2081.
13. Socinski M.A., Cannistra S.A., Elias A., et al. Granulocyte-macrophage colony-stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988, 1:1194-1198.
14. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996, 17:691-697.
15. Haas R., Mohle R., Fruhauf S., et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994, 83:3787-3794.
16. Seggewiss R., Buss E.C., Herrmann D., et al. Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy. Stem Cells 2003, 21:568-574.
17. Moskowitz C.H., Bertino J.R., Glassman J.R., et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:3776-3785.
18. Kewalramani T., Zelenetz A.D., Nimer S.D., et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004, 103:3684-3688.
19. Bishton M.J., Lush R.J., Byrne J.L., et al. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007, 136:752-761.
20. Pavone V., Gaudio F., Guarini A., et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002, 29:285-290.
21. Fruehauf S., Seggewiss R. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected]. Br J Haematol 2003, 122:360-375.
22. Bonig H., Wundes A., Chang K.H., Lucas S., et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d-blocking antibody natalizumab. Blood 2008, 111:3439-3441.
23. + hematopoietic progenitor cells in humans. Blood 2008, 111:3893-3895.
24. Liu W., Wang L., Shang X., et al. Mobilization of hematopoitic stem/progenitor cells by a Cdc42 activity-specific inhibitor. Blood 2008, 112:32-33.
25. Yang L., Wang L., Geiger H., et al. Rho GTPase Cdc42 coordinates hematopoietic stem cell quiescence and niche interaction in the bone marrow. Proc Natl Acad Sci USA 2007, 104:5091-5096.
26. Ramirez P.A., Rettig M., Holt M., et al. Rapid mobilization of long-term repopulating hematopoietic stem cells (HSC) with AMD15057, a small-molecule inhibitor of VLA4: synergism with AMD3100 and G-CSF. Blood 2008, 112:229-230.
27. Immunobiology 2005, Garland Science Publishers, New York. C.A. Janeway, P. Travers, M. Walport (Eds.).
28. + B cell precursors. Stem Cells 1994, 12:95-102.
29. + cells in peripheral and cord blood by flow cytometry. Exp Hematol 1994, 22:1003-1010.
30. Kollet O., Dar A., Shivtiel S., et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006, 12:657-664.
31. Lapidot T., Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002, 16:1992-2003.
32. Papayannopoulou T., Priestley G.V., Nakamoto B., et al. Synergistic mobilization of hemopoietic progenitor cells using concurrent beta1 and beta2 integrin blockade or beta2-deficient mice. Blood 2001, 97:1282-1288.
33. + stem/progenitor cells to bone marrow. Blood 2004, 103:2981-2989.
34. + hematopoietic progenitor cells. Blood 1997, 89:3522-3528.
35. Richman C.M., Weiner R.S., Yankee R.A. Increase in circulating stem cells following chemotherapy in man. Blood 1976, 47:1031-1039.
36. Levesque J.P., Hendy J., Takamatsu Y., et al. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002, 30:440-449.
37. Heissig B., Hattori K., Dias S., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9-mediated release of kit-ligand. Cell 2002, 109:625-637.
38. Levesque J.P., Takamatsu Y., Nilsson S.K., et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001, 98:1289-1297.
39. Petit I., Szyper-Kravitz M., Nagler A., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002, 3:687-694.
40. Semerad C.L., Christopher M.J., Liu F., et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005, 106:3020-3027.
41. Martin C., Burdon P.C., Bridger G., et al. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003, 19:583-593.
42. Martin C., Bridger G.J., Rankin S.M. Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro. Br J Haematol 2006, 134:326-329.
43. Hatse S., Princen K., Bridger G., et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002, 527:255-262.
44. Fricker S.P., Anastassov V., Cox J., et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 2006, 72:588-596.
45. Gerlach L.O., Skerlj R.T., Bridger G.J., et al. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001, 276:14153-14160.
46. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
47. + cells in elderly patients (≥70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003, 120:413-423.
48. Hosing C., Saliba R., Ahlawat S., et al. Poor hematopoietic stem cell mobilizers: a single-institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009, 84:335-337.
49. Bensinger W., Appelbaum F., Rowley S., et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995, 13:2547-2555.
50. Demirer T., Buckner C.D., Gooley T., et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996, 17:937-941.
51. Dreger P., Kloss M., Petersen B., et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995, 86:3970-3978.
52. Lee J.L., Kim S.B., Lee G.W., et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apher Sci 2003, 29:29-37.
53. Moskowitz C.H., Stiff P., Gordon M.S., et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients: results of a phase I/II trial. Blood 1997, 89:3136-3147.
54. Sugrue M.W., Williams K., Pollock B.H., et al. Characterization and outcome of " hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000, 39:509-519.
55. Gordan L.N., Sugrue M.W., Lynch J.W., et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003, 44:815-820.
56. Paripati H., Stewart A.K., Cabou S., et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008, 22:1282-1284.
57. Popat U., Saliba R., Thandi R., et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009, 15:718-723.
58. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
59. + cells in multiple myeloma. Ann Hematol 2001, 80:592-597.
60. Micallef I.N., Apostolidis J., Rohatiner A.Z., et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000, 1:367-373.
61. + haematopoietic progenitor cells in patients older than 60 years with non-Hodgkin's lymphoma or multiple myeloma. Bone Marrow Transplant 2009, 42:105.
62. Stiff P., Micallef I., McCarthy P., et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009, 15:249-256.
63. Micallef I.N.M., Tarantolo S.R., McSweeney P.A., et al. Plerixafor can predictably mobilize hematopoietic stem cells in patients with multiple myeloma previously treated with lenalidomide [abstract]. Haematologica 2009, 94:292.
64. Schriber J.R.S., McCarty J.M., McGuirk J.M., et al. Plerixafor can predictably mobilize hematopoietic stem cells in patients with non-Hodgkin's lymphoma previously treated with fludarabine and undergoing autologous stem cell transplantation [abstract]. Haematologica 2009, 94:289.
65. + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
66. Micallef I.N., Stiff P.J., DiPersio J.F., et al. Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009, 15:1578-1586.
67. ®) plus G-CSF is effective in mobilizing hematopoietic stem cells in patients with concurrent thrombocytopenia undergoing autologous hematopoietic stem cell transplantation [abstract]. Blood 2009, 114:1251.
68. Ivanovic Z, Kovacevic-Filipovic M, Jeanne M, et al. CD34+ cells obtained from " good mobilizers" are more activated and exhibit lower ex vivo expansion efficiency than their counterparts from " poor mobilizers." Transfusion., published online ahead of print, Oct 12, 2009. PMID: 19821946.
69. Franklin W.A., Glaspy J., Pflaumer S.M., et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood 1999, 94:340-347.
70. Billadeau D., Quam L., Thomas W., et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992, 80:1818-1824.
71. Lemoli R.M., Cavo M., Fortuna A. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma. J Hematother 1996, 5:339-349.
72. Demirkazik A., Kessinger A., Armitage J.O., et al. Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation. Bone Marrow Transplant 2001, 28:207-212.
73. Gribben J.G., Neuberg D., Freedman A.S., et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993, 81:3449-3457.
74. Gertz M.A., Witzig T.E., Pineda A.A., et al. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997, 19:337-342.
75. Kopp H.G., Yildirim S., Weisel K.C., et al. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. J Cancer Res Clin Oncol 2009, 135:637-642.
76. Vogel W., Kopp H.G., Kanz L., et al. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol 2005, 131:214-218.
77. Stewart A.K., Vescio R., Schiller G., et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001, 19:3771-3779.
78. + cell selection: long-term follow-up of an EBMT phase III randomized study. Haematologica 2007, 92:1083-1090.
79. Ho J., Yang L., Banihashemi B., et al. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2009, 43:223-228.
80. Mateo G., Corral M., Almeida J., et al. Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma. Haematologica 2003, 88:1013-1021.
81. Ross A.A., Cooper B.W., Lazarus H.M., et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993, 82:2605-2610.
82. Kessinger A., Armitage J.O., Smith D.M., et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989, 74:1260-1265.
83. Moss T.J., Sanders D.G., Lasky L.C., et al. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990, 76:1879-1883.
84. Vose J.M., Sharp G., Chan W.C., et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002, 20:2344-2352.
85. Vescio R.A., Han E.J., Schiller G.J., et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 1996, 18:103-110.
86. Kanteti R., Miller K., McCann J., et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Bone Marrow Transplant 1999, 24:473-481.
87. Leonard B.M., Hetu F., Busque L., et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998, 91:331-339.
88. Kiel K., Cremer F.W., Ehrbrecht E., et al. First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield. Bone Marrow Transplant 1998, 21:1109-1115.
89. Lincz L.F., Crooks R.L., Way S.L., et al. Tumour kinetics in multiple myeloma before, during, and after treatment. Leuk Lymphoma 2001, 40:373-384.
90. Gazitt Y., Tian E., Barlogie B., et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1996, 87:805-811.
91. Cremer F.W., Kiel K., Wallmeier M., et al. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol 1998, 26:969-975.
92. Anagnostopoulos A., Aleman A., Yang Y., et al. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant 2004, 33:623-628.
93. Narayanasami U., Kanteti R., Morelli J., et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001, 98:2059-2064.
94. Fruehauf S., Ehninger G., Hubel K., et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010, 45:269-275.
95. Tricot G., Cottler-Fox M., Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010, 45:63-68.
96. DiPersio J.F., Bridger G., Calandra G. Effect of plerixafor (AMD 3100) plus G-CSF on tumor cell mobilization among patients with lymphoma [abstract]. Biol Blood Marrow Transplant 2009, 15:37.
97. + cells with a different antigenic profile compared with use during steady-state hematopoiesis. Bone Marrow Transplant 1994, 14:827-832.
98. + hematopoietic progenitor cells. Blood 1995, 85:1936-1943.
99. + cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 1995, 13:1922-1932.
100. - cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Bone Marrow Transplant 1998, 22:469-475.
101. Benboubker L., Binet C., Cartron G., et al. Frequency and differentiation capacity of circulating LTC-IC mobilized by G-CSF or GM-CSF following chemotherapy: a comparison with steady-state bone marrow and peripheral blood. Exp Hematol 2002, 30:74-81.
102. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
103. Rissoan M.C., Soumelis V., Kadowaki N., et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999, 283:1183-1186.
104. Arpinati M., Green C.L., Heimfeld S., et al. Granulocyte colony-stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000, 95:2484-2490.
105. Xia G., Truitt R.L., Johnson B.D. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 2006, 12:397-407.
106. Porrata L.F., Gastineau D.A., Padley D., et al. Re-infused autologous graft natural killer cells correlate with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003, 44:997-1000.
107. Porrata L.F., Gertz M.A., Geyer S.M., et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004, 18:1085-1092.
108. Porrata L.F., Litzow M.R., Inwards D.J., et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33:291-298.
109. Wolf D., Wolf A.M., Fong D., et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2007, 83:1107-1113.
110. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108:1291-1297.
111. Waller E.K., Rosenthal H., Sagar L. DC2 effect on survival following allogeneic bone marrow transplantation. Oncology (Williston Park) 2002, 16:19-26.
112. Wierenga P.K., Setroikromo R., Kamps G., et al. Peripheral blood stem cells differ from bone marrow stem cells in cell cycle status, repopulating potential, and sensitivity toward hyperthermic purging in mice mobilized with cyclophosphamide and granulocyte colony-stimulating factor. J Hematother Stem Cell Res 2002, 11:523-532.
113. Neben S., Marcus K., Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 1993, 81:1960-1967.
114. Yamamoto Y., Yasumizu R., Amou Y., et al. Characterization of peripheral blood stem cells in mice. Blood 1996, 88:445-454.
115. Morrison S.J., Wright D.E., Weissman I.L. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci USA 1997, 94:1908-1913.
116. Pan L., Delmonte J., Jalonen C.K., et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995, 86:4422-4429.
117. Fukuda S., Bian H., King A.G., et al. The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood 2007, 110:860-869.
118. Pelus L.M., Singh P. The combination of AMD3100 plus GRO{beta} rapidly mobilizes hematopoietic stem cells with enhanced homing, adhesion and survival properties [abstract]. Blood 2008, 112:34.
119. Osawa M., Hanada K., Hamada H., et al. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996, 273:242-245.
120. Matsuzaki Y., Kinjo K., Mulligan R.C., et al. Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. Immunity 2004, 20:87-93.
121. Cocks B.G., Chang C.C., Carballido J.M., et al. A novel receptor involved in T-cell activation. Nature 1995, 376:260-263.
122. Killeen N., Stuart S.G., Littman D.R. Development and function of T cells in mice with a disrupted CD2 gene. EMBO J 1992, 11:4329-4336.
123. Gonzalez-Cabrero J., Wise C.J., Latchman Y., et al. CD48-deficient mice have a pronounced defect in CD4(+) T cell activation. Proc Natl Acad Sci USA 1999, 96:1019-1023.
124. + cells mobilized by G-CSF. Bone Marrow Transplant 1998, 21:561-568.
125. Dazzi C., Cariello A., Rosti G., et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?. Leuk Lymphoma 2000, 39:301-310.
126. Alegre A., Tomas J.F., Martinez-Chamorro C., et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997, 20:211-217.
127. Koc O.N., Gerson S.L., Cooper B.W., et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000, 18:1824-1830.
128. Fruehauf S., Veldwijk M.R., Seeger T., et al. A combination of granulocyte colony-stimulating factor (G-CSF) and AMD3100 (plerixafor) mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009, 11:992-1001.
129. Vela-Ojeda J., Garcia-Ruiz Esparza M.A., Reyes-Maldonado E., et al. Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma. Ann Hematol 2006, 85:308-314.
130. Morse M.A., Vredenburgh J.J., Lyerly H.K. A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. J Hematother Stem Cell Res 1999, 8:577-584.
131. Gazitt Y., Akay C., Thomas C. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-Hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF. Stem Cells Dev 2006, 15:269-277.
132. Gazitt Y., Shaughnessy P., Devore P. Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001, 10:177-186.
133. Ferrari S., Rovati B., Porta C., et al. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor. Cancer Immunol Immunother 2003, 52:359-366.
134. Lonial S., Hicks M., Rosenthal H., et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant 2004, 10:848-857.
135. + cells and dendritic cells by AMD3100 plus granulocyte colony-stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev 2007, 16:657-666.
136. Condomines M., Quittet P., Lu Z.Y., et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol 2006, 176:6631-6639.
137. Holtan S.G., Porrata L.F., Micallef I.N., et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007, 7:315-318.
138. Hess D.A., Bonde J., Craft T.P., et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony-stimulating factor. Biol Blood Marrow Transplant 2007, 13:398-411.
139. Menendez P., Caballero M.D., Prosper F., et al. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. Transfusion 2002, 42:1159-1172.
140. + cells from steady-state bone marrow and peripheral blood mobilized following G-CSF-supported chemotherapy. Stem Cells 1998, 16:271-279.
141. - subsets: collection and engraftment kinetics in autologous peripheral blood stem cells transplantation. Haematologica 1998, 83:489-495.
142. Dean R., Masci P., Pohlman B., et al. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and posttransplant recovery predict survival. Bone Marrow Transplant 2005, 36:1049-1052.
143. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide, which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004, 34:336-344.
144. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868.
145. + Treg) [abstract]. Blood 2008, 112:806.
146. Woo E.Y., Yeh H., Chu C.S., et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002, 168:4272-4276.
147. Liyanage U.K., Moore T.T., Joo H.G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-2761.
148. Marshall N.A., Christie L.E., Munro L.R., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103:1755-1762.
149. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
150. +CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004, 173:1444-1453.
151. + regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008, 111:5359-5370.
152. Elquza E., Spier C., Fiederlein R., et al. Effects of mobilization with granulocyte colony-stimulating factor (G-CSF) and plerixafor on lymphocyte subsets in autologous peripheral blood stem cell (PBSC) apheresis products. Blood 2009, 114:843-844.
153. + cells mobilized into peripheral blood. Bone Marrow Transplant 1998, 22(Suppl 5):S47-S50.
154. + hematopoietic stem cells following administration of G-CSF or plerixafor [abstract]. Blood 2008, 112:1192.
155. Toh H.C., Sun L., Soe Y., et al. G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo. Clin Immunol 2009, 132:83-92.
156. + Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995, 86:2842-2848.
157. Dreger P., Haferlach T., Eckstein V., et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994, 87:609-613.
158. + hematopoietic cells from normal human volunteers stimulated with granulocyte colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45:295-300.
159. Devine S.M., Vij R., Rettig M., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112:990-998.
160. + plasmacytoid dendritic cell precursors by plerixafor [abstract]. Blood 2009, 114:19.
161. + selected blood cells from HLA-identical siblings. Blood 2002, 100:724-727.
162. + cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. Biol Blood Marrow Transplant 2007, 13:1515-1524.
163. Tayebi H., Kuttler F., Saas P., et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol 2001, 29:458-470.
164. Uchida N., He D., Friera A.M., et al. The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. Blood 1997, 89:465-472.
165. + cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor. Blood 1997, 89:1189-1196.
166. + hematopoietic stem cells. Blood 2002, 99:2037-2044.
167. + cell populations based on global gene and microRNA expression signatures. Blood 2009, 114:2530-2541.
168. Larochelle A., Krouse A., Metzger M., et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006, 107:3772-3778.
169. Bonig H., Chudziak D., Priestley G., et al. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol 2009, 37:402-415.
170. + cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. Stem Cells 2001, 19:37-45.
171. Oelschlaegel U., Bornhauser M., Boxberger S., et al. Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilization with G-CSF plus AMD3100 in patients with multiple myeloma. Ann Hematol 2007, 86:569-573.
172. Fruehauf S., Seeger T., Maier P., et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol 2006, 34:1052-1059.
173. Jin P., Wang E., Ren J., et al. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med 2008, 6:39.
174. Dlubek D., Drabczak-Skrzypek D., Lange A. Low CXCR4 membrane expression on CD34(+) cells characterizes cells mobilized to blood. Bone Marrow Transplant 2006, 37:19-23.
175. Amariglio N., Jacob-Hirsch J., Shimoni A., et al. Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors. Acta Haematol 2007, 117:68-73.
176. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
177. Bonig H., Priestley G.V., Oehler V., et al. Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC. Exp Hematol 2007, 35:326-334.
178. Drouet M., Herodin F., Norol F., et al. Cell cycle activation of peripheral blood stem and progenitor cells expanded ex vivo with SCF, FLT-3 ligand, TPO, and IL-3 results in accelerated granulocyte recovery in a baboon model of autologous transplantation but G0/G1 and S/G2/M graft cell content does not correlate with transplantability. Stem Cells 2001, 19:436-442.
179. Burroughs L., Mielcarek M., Little M.T., et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005, 106:4002-4008.
180. + cells is related to hematopoietic recovery after autologous stem cell transplantation. Blood 2001, 97:799-804.
181. + cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood 1995, 85:3313-3319.
182. + cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999, 4:195-209.
183. Weaver C.H., Hazelton B., Birch R., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995, 86:3961-3969.
184. + cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. Eur J Cancer 2000, 36:2360-2367.
185. -) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. J Immunol 1997, 158:5169-5177.
186. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995, 74:521-525.
187. + progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant 2007, 40:851-857.
188. Hogge D.E., Lambie K., Sutherland H.J., et al. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post-autologous transplant. Bone Marrow Transplant 2000, 25:589-598.
189. + T-cell receptor-negative cells that facilitate bone marrow repopulation with hematopoietic stem cells. Blood 2008, 111:1735-1738.
190. Larochelle A., Vormoor J., Hanenberg H., et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 1996, 2:1329-1337.
191. - progenitor cells. Blood 1991, 77:1218-1227.
192. Dahl E., Burroughs J., DeFor T., et al. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood. Bone Marrow Transplant 2003, 32:575-580.
193. Sutherland H.J., Eaves C.J., Lansdorp P.M., et al. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants. Blood 1994, 83:3808-3814.
194. Klaus J., Herrmann D., Breitkreutz I., et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2007, 78:21-28.
195. Haas R., Witt B., Mohle R., et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995, 85:3754-3761.
196. Porrata L.F., Inwards D.J., Micallef I.N., et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002, 117:629-633.
197. Gordan L.N., Sugrue M.W., Lynch J.W., et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 2003, 31:1009-1013.
198. Waller E.K., Rosenthal H., Jones T.W., et al. Larger numbers of CD4 (bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001, 97:2948-2956.
199. Skert C., Damiani D., Michelutti A., et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant 2009, 44:729-737.
200. Xu L.P., Luo X.H., Chang Y.J., et al. High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. Ann Hematol 2009, 88:1015-1024.
201. Zeng D., Dejbakhsh-Jones S., Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997, 90:453-463.
202. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
203. Powles R., Mehta J., Kulkarni S., et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000, 355:1231-1237.
204. - memory T cells without graft-versus-host disease. Blood 2004, 103:1534-1541.
205. + naive T cells: potential for adoptive immunotherapy and allodepletion. Blood 2004, 104:2403-2409.
206. Morris E.S., MacDonald K.P., Rowe V., et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 2004, 103:3573-3581.
207. Hoffmann P., Ermann J., Edinger M., et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
208. Cohen J.L., Trenado A., Vasey D., et al. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002, 196:401-406.
209. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+) CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
210. Ruzek M.C., Waire J.S., Hopkins D., et al. Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo. Blood 2008, 111:1726-1734.
211. Smith A.L., Jungnam J., Rao S., et al. Significant alterations in T-cell TH1 and TH2 cytokine gene profiles associated with G-CSF mobilization do not occur in T cells mobilized with AMD3100 [abstract]. Blood 2007, 110:962a.
212. Fruehauf S., Haas R., Conradt C., et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 1995, 85:2619-2626.
213. Fruehauf S., Schmitt K., Veldwijk M.R., et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor-supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999, 105:786-794.
214. Sinha S., Gastineau D.A., Hogan W.J., et al. Predicting poor peripheral blood stem cell mobilization in multiple myeloma (MM) using initial peripheral CD34 counts: developing target-based cut-points for early intervention. Blood 2009, 114:1252-1253.
215. Micallef I., Ansell S.M., Buadi F., et al. A risk-adapted approach utilizing plerixafor in autologous peripheral blood stem cell mobilization [abstract]. Blood 2009, 114:1244.
216. + cell counts [abstract]. Blood 2009, 114:1252.
217. Alexander E., Costa L.J., Taylor M., et al. Cost-effective use of plerixafor for hematopoietic stem cell mobilization: development and validation of a decision-making algorithm [abstract]. Blood 2009, 114:1246.
218. - cells in posttransplant hematopoietic recovery. Stem Cells 1998, 16(Suppl 1):113-122.